G-protein-coupled receptor 30 interacts with receptor activity-modifying protein 3 and confers sex-dependent cardioprotection

Patricia M Lenhart, Stefan Broselid¹, Cordelia J Barrick, L M Fredrik Leeb-Lundberg¹ and Kathleen M Caron

Department of Cell Biology and Physiology, The University of North Carolina, CB #7545, 6340B MBRB, 111 Mason Farm Road, Chapel Hill, North Carolina 27599, USA
¹Department of Experimental Medical Science, Lund University, SE-22184 Lund, Sweden

Abstract

Receptor activity-modifying protein 3 (RAMP3) is a single-pass transmembrane protein known to interact with and affect the trafficking of several G-protein-coupled receptors (GPCRs). We sought to determine whether RAMP3 interacts with GPR30, also known as G-protein-coupled estrogen receptor 1. GPR30 is a GPCR that binds estradiol and has important roles in cardiovascular and endocrine physiology. Using bioluminescence resonance energy transfer titration studies, co-immunoprecipitation, and confocal microscopy, we show that GPR30 and RAMP3 interact. Furthermore, the presence of GPR30 leads to increased expression of RAMP3 at the plasma membrane in HEK293 cells. In vivo, there are marked sex differences in the subcellular localization of GPR30 in cardiac cells, and the hearts of Ramp3⁰⁻ mice also show signs of GPR30 mislocalization. To determine whether this interaction might play a role in cardiovascular disease, we treated Ramp3⁰⁻ and Ramp3⁰ mice on a heart disease-prone genetic background with G-1, a specific agonist for GPR30. Importantly, this in vivo activation of GPR30 resulted in a significant reduction in cardiac hypertrophy and perivascular fibrosis that is both RAMP3 and sex dependent. Our results demonstrate that GPR30–RAMP3 interaction has functional consequences on the localization of these proteins both in vitro and in vivo and that RAMP3 is required for GPR30-mediated cardioprotection.

Key Words
- G-protein-coupled receptors
- estradiol
- cardiac hypertrophy
- cardioprotection

Introduction

Receptor activity-modifying proteins (RAMPs) are single-pass transmembrane-accessory proteins that interact with G-protein-coupled receptors (GPCRs) to modulate their trafficking, ligand-binding specificity, and downstream signaling. The RAMPs were first identified in association with calcitonin receptor-like receptor (CLR; McLatchie et al. 1998, Bomberger et al. 2012) – a discovery that clarified considerable controversy over CLR function and has since been exploited by the pharmaceutical industry for the development of small-molecule drugs that specifically target the RAMP–CLR interface (Sexton et al. 2009). Several additional GPCRs have been shown to interact with RAMPs (Christopoulos et al. 2003, Harikumar et al. 2009). Therefore, there remains great interest in understanding the pharmacological and biochemical properties of the RAMPs and in continuing to identify novel GPCR
targets for these proteins, with the ultimate goal of manipulating the RAMP–GPCR interface for treatment of human disease.

RAMP3 is unique among the RAMP family members in that it is transcriptionally induced by estradiol (E2; Hewitt et al. 2005, Watanabe et al. 2006) and has been shown to play a sex-dependent role in the development of cardiac hypertrophy and transition to heart failure (Barrick et al. 2012). For these reasons, we considered that GPR30, or G-protein-coupled estrogen receptor 1, might be a candidate RAMP3-binding GPCR. GPR30 binds E2 with high affinity, eliciting rapid intracellular signaling (Carmeci et al. 1997, Filardo et al. 2007), and mediates pleiotropic functions in the cardiovascular, endocrine, immune, and central nervous systems (Olde & Leeb-Lundberg 2009, Nilsson et al. 2011, Prosnitz & Barton 2011).

There is substantial evidence for GPR30-mediated cardioprotection. GPR30 is expressed in the rodent and human hearts (Deschamps & Murphy 2009, Patel et al. 2010), and using male rats, Filice et al. (2009) showed that GPR30 is involved in mediating the effects of E2 in the heart. Numerous studies have explored the effects of pharmacological activation of GPR30 with G-1, a synthetic agonist for GPR30 that specifically activates GPR30 but does not activate the steroid E2 receptors (Bologa et al. 2006). Administration of G-1 is directly cardioprotective, reducing infarct size in rat and mouse hearts exposed to ischemia–reperfusion (Deschamps & Murphy 2009, Bopassa et al. 2010). Furthermore, chronic G-1 treatment reduces left ventricular wall thickness and myocyte hypertrophy without significant effects on blood pressure or fibrosis in a rat model of salt-induced hypertension (Jessup et al. 2010) and attenuates heart failure (Kang et al. 2012) and diastolic dysfunction independent of blood pressure in ovariectomized female rats (Wang et al. 2012). Based on these preclinical studies, pharmacological activation of GPR30 as a potential therapeutic intervention could have utility in the treatment of cardiovascular disease.

Despite what is known about GPR30, there remains intense controversy regarding the trafficking and subcellular localization of GPR30, in addition to many conflicting reports regarding its downstream signaling and even ligand-binding specificity. As RAMPs serve to modulate these aspects of GPCR behavior, we hypothesized that an interaction with RAMPs could potentially clarify some of the controversies surrounding GPR30. Specifically, we sought to determine whether RAMP3, an E2-induced accessory protein known to be important in cardiovascular disease, could interact with and modulate the function of GPR30, as an E2 receptor with protective roles in cardiac and vascular biology.

Materials and methods

Animals

Ramp3−/− animals were generated as described previously (Dackor et al. 2007) and Ramp3+/+ and Ramp3−/− mice were crossed to heterozygous RenTgMK mice (Barrick et al. 2012). Experimental animals were 8 weeks of age and maintained on an isogenic 129S6/SvEv genetic background. All experiments were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill.

Bioluminescence resonance energy transfer

Bioluminescence resonance energy transfer (BRET) titration studies to test the molecular association between GPR30 and RAMP3 were carried out as described previously (Heroon et al. 2007). Briefly, the calcium phosphate precipitation method was used to transfect HEK293 cells with a constant amount of hGPR30-RLuc, hCLR-RLuc (positive control), hB2AR-RLuc, or hD1R-RLuc (negative controls) and increasing doses of hRAMP3–YFP. Cells were treated with the luciferase substrate coelenterazine H for 10 min and read using a Berthold Technologies Mithras (Bad Wildbad, Germany) LB940 plate reader. BRET signal was calculated as the ratio of light emitted from YFP (530 nm) to light emitted from RLuc (485 nm). Total fluorescence emission was measured at 530 nm from wells not treated with coelenterazine H that were excited at 485 nm to control for the expression level of hRAMP3–YFP, and total luminescence was determined to control for the expression level of the receptors. Results were analyzed using GraphPad Prism. Results shown are representative of at least three replicate BRET experiments that were performed with similar results.

Co-immunoprecipitation

HEK293 cells were transfected with HA-RAMP3 and FLAG-GPR30 using TransIT-293 (Mirus, Madison, WI, USA), and GPR30 was immunoprecipitated by incubating the cleared cell lysates overnight at 4 ºC with M2 FLAG antibody beads (Sigma–Aldrich). The precipitate was washed extensively and sequentially in lysis buffer and in 10 mM Tris–HCl, pH 7.4. For immunoblotting, proteins were denatured in SDS–PAGE sample buffer including 6% β-mercaptoethanol for 30 min at 37 ºC, fractionated by SDS–PAGE, transferred...
to a nitrocellulose membrane, and the membrane was blocked for at least 45 min in Tris-buffered saline and 10% nonfat milk. The proteins were stained by incubating with rabbit anti-HA antibody (Invitrogen; 1:1000) for 1 h at room temperature. Immunoreactive bands were visualized with a chemiluminescence kit using anti-rabbit peroxidase-labeled secondary antibody according to the procedure described by the supplier (PerkinElmer Life (Waltham, MA, USA) and Analytical Sciences (Petaluma, CA, USA)).

Confocal imaging

HEK293 cells were transfected with HA-RAMP3 and FLAG-GPR30 using TransIT-293 (Mirus). Transfected cells were grown on glass coverslips coated with poly(L-lysine) and then incubated in serum- and phenol-free media for at least 1 h at 37°C. For live cell staining, cells were then incubated in serum- and phenol-free media containing IgG1 monoclonal anti-HA (1:100; Covance, Raleigh, NC, USA) and IgG2b monoclonal anti-M1 FLAG (1:500; Sigma–Aldrich) primary antibodies for 30 min at 37°C. Cells were fixed with 3.7% formaldehyde in PBS and permeabilized, then washed with PBS, and incubated with anti-IgG1-488 and anti-IgG2b-568 secondary antibodies (Invitrogen). Alternatively, for dead cell staining, cells were incubated with both primary and secondary antibodies after fixation. Cells were also stained with 4′,6-diamidino-2-phenylindole (DAPI). Images were collected using a Nikon Eclipse confocal fluorescence microscope (Nikon, Tokyo, Japan) and analyzed with Nikon EC-Z1 3.90 Software.

Gene expression analysis

mGpr30 and mRamp3 gene expression was analyzed by quantitative RT-PCR with the Applied Biosystems StepOne Plus machine. The primer/probe set for Ramp3 has been described previously (Dackor et al. 2007). For Gpr30, we used a pre-designed Assay on Demand primer/probe set (#Mm02620446_s1, Applied Biosystems). Mouse eukaryotic translation elongation factor 1 alpha 1 was used as the internal control for all samples; the primer/probe set has been described previously (Barrick et al. 2012). RNA was isolated from adult tissues with TRIzol reagent (Life Technologies) and subsequently DNase treated. Two micrograms of total RNA was used to generate cDNA with the MMLV Reverse Transcriptase Kit (Life Technologies). The ΔΔCt method was used to determine the relative levels of gene expression and was shown as a fold increase over wild-type male controls. Estrus cycle phase was determined by microscopic examination of mouse vaginal smears stained with the Kwik Diff Stain Kit (Thermo Scientific). For the ovariectomized samples, mice were 21–28 days old at the time of ovariectomy. Mice were anesthetized with avertin (0.2–0.4 ml/10 g body weight (BW) of 1.25% solution) and placed on a warm heating pad to maintain body temperature throughout the surgical procedure. Hair was removed from the abdomen and a small (<1 cm) incision was made through the abdominal wall about 1 cm to the left of the spinal cord. The ovary was exteriorized and placed on a sterile drape. Silk sutures were used to ligate the oviduct and anterior connective tissue before excising the ovary. The body wall was then sutured with dissolvable sutures and wound clips were used to close the skin. The procedure was repeated on the animal’s right side. Wound clips were removed 4–5 days after surgery; 4 weeks later, the ovariectomized mice were dissected and the heart tissue was used for RT-PCR.

Subcellular fractionation and western blotting

Homogenized lysates were prepared from heart tissue of Ramp3+/+, Ramp3−/−, RenTgMK;Ramp3+/+, and RenTgMK; Ramp3−/− male and female mice. The nuclear pellet was removed by centrifuging at 1300 g for 1 h. Membrane-enriched fractions of cardiac lysates were isolated by subsequent ultracentrifugation at 20 000 g for 1 h, and the remaining supernatant was designated as the cytosolic fraction. Lysates were denatured in SDS–PAGE sample buffer including 6% β-mercaptoethanol for 5 min at 100°C, fractionated by SDS–PAGE, transferred to a nitrocellulose membrane, and the membrane was blocked for 1 h in casein (Thermo Scientific). The membrane was stained using rabbit anti-GPR30 primary antibody (MBL International, Woburn, MA, USA) or mouse anti-actin (Sigma–Aldrich) as a loading control, followed by goat anti-rabbit 680 or goat anti-mouse 800 secondary antibody (Thermo Scientific). Membranes were imaged via LI-COR, and quantitation of integrated density normalized to actin was performed using the free ImageJ software. The Student’s t-test was used to compare the ratio of plasma membrane to cytosolic GPR30 protein relative to actin, and a value of P<0.05 was considered statistically significant. Results shown are representative of at least three replicate fractionation experiments that were performed with similar results.

G-1 treatment and histology

Male and female RenTgMK;Ramp3+/+ and RenTgMK; Ramp3−/− mice at 8 weeks of age were anesthetized with
avertin (0.2–0.4 ml/10 g BW of 1.25% solution) and injected with a s.c., continuous release pellet (Innovative Research of America, Sarasota, FL, USA) containing 6 mg G-1 (Tocris, Bristol, UK) or placebo similar to a previously described method (Wang et al. 2009). After 40 days of treatment, the mice were killed. To determine the left ventricle to BW (LV:BW) ratio, the heart chambers were dissected and the LV was weighed. The Mann–Whitney U test was used to compare LV:BW data; a value of P<0.05 was considered statistically significant. Subsequently, the LV was fixed in 4% paraformaldehyde and 5 μm sections were prepared for staining. Masson’s trichrome-stained slides imaged at 10× were used to analyze interstitial and perivascular cardiac fibrosis. Interstitial fibrosis was quantified by blinded scoring of the extent of interstitial fibrosis in one representative field per mouse. Perivascular fibrosis was quantified by measuring the area of fibrosis surrounding a vessel normalized to the vessel lumen area, using ImageJ Software. Three vessels were measured per mouse. Cardiomyocyte area was determined by measuring the cross-sectional area of five cardiomyocytes in each of two fields per mouse from hematoxylin and eosin-stained slides at 25×, using ImageJ Software. For analysis of fibrosis and cardiomyocyte area, the Student’s t-test was used to compare data and a value of P<0.05 was considered statistically significant.

Blood pressure measurements

Male and female RenTgMK;Ramp3+/+ and RenTgMK; Ramp3−/− mice at 2–5 months of age were injected with a s.c., continuous release pellet containing 6 mg of G-1 or placebo as described earlier. Blood pressures were measured on unanesthetized mice using a Coda computerized volume pressure recording tail cuff system (Kent Scientific, Torrington, CA, USA). After a 5-day period of acclimation to the tail cuff system, blood pressures were measured daily for 5 days on each mouse during the third week following pellet injection. The Student’s t-test was used to compare data; a value of P<0.05 was considered statistically significant.

Results

To directly test whether GPR30 and RAMP3 interact in living cells, we utilized BRET (Heroux et al. 2007) titration studies. HEK293 cells were transfected with a constant dose of hGPR30–RLuc and increasing doses of hRAMP3–YFP. We observed a robust increase in the BRET signal with increasing amounts of hRAMP3 (ΔBRET=0.664), indicating a specific interaction between the two proteins (Fig. 1A). Almost no change in BRET signal was seen with the negative controls, β2-adrenergic receptor (ΔBRET=-0.061), and dopamine-1 receptor (ΔBRET=0.079). The positive increase in BRET signal observed for hGPR30 and hRAMP3 was an order of magnitude greater than the negative controls and comparable to that seen with the positive control, hCLR (ΔBRET=0.728).

To further confirm that hGPR30 and hRAMP3 interact, we performed co-immunoprecipitation. In cells transfected with either FLAG-hGPR30 alone or with HA-hRAMP3, we immunoprecipitated with M2-FLAG beads and immunoblotted for HA (Fig. 1B). The M2-FLAG beads pull down HA material only when FLAG-hGPR30 and HA-hRAMP3 are co-expressed, indicating by a second technique that GPR30 and RAMP3 interact.

The ability of GPCRs to enhance the localization of RAMPs in the plasma membrane is the standard method in the field by which the association of receptors with RAMPs has been tested (Harikumar et al. 2009). Therefore, we imaged the interaction of GPR30 and RAMP3 by confocal microscopy of HEK293 cells transiently transfected with HA-hRAMP3 and FLAG-hGPR30 and stained with epitope-specific antibodies. The top row of Fig. 2A shows cells stained following fixation to identify total cellular proteins. In this representative field, cells are present

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0021 © 2013 Society for Endocrinology
Published by Bioscientifica Ltd.
expressing HA-hRAMP3 alone and together with FLAG-hGPR30. When expressed alone, diffuse RAMP3 staining occurs throughout the cell. On the other hand, co-expression with GPR30 organizes RAMP3 staining and extensive co-localization occurs in the plasma membrane and intracellularly on filamentous structures and in puncta. Figure 2B shows cells stained live and imaged after fixation to identify cell surface proteins. In this representative field, cells are present expressing HA-hRAMP3 and FLAG-hGPR30 individually and together. When expressed alone, RAMP3 is primarily in intracellular puncta. On the other hand, co-expression with GPR30 increases the relative amount of RAMP3 staining at the cell surface and extensive co-localization occurs. Thus, the formation of a GPR30–RAMP3 complex within the cell increases RAMP3 localization to the plasma membrane.

Figure 2
Localization of GPR30 and RAMP3 in vitro. (A) Fixed cell staining, confocal microscopy of HEK293 cells transfected with HA-hRAMP3 (green in merged panel) and FLAG-hGPR30 (red in merged panel) stained fixed with M1 FLAG antibody and anti-HA antibody and then with secondary antibody. Left panel shows the FLAG-hGPR30 channel alone, the middle panel shows the HA-hRAMP3 channel alone (arrow indicates a cell expressing only HA-hRAMP3), and the right panel shows the two channels merged with DAPI nuclear stain in blue (arrow indicates a cell expressing both FLAG-hGPR30 and HA-hRAMP3). (B) Live cell staining, HEK293 cells were similarly transfected and stained live with M1 FLAG antibody and anti-HA antibody followed by fixing and staining with secondary antibody. The left panel shows the FLAG-hGPR30 channel alone (arrow indicates a cell expressing only FLAG-hGPR30), the middle panel shows the HA-hRAMP3 channel alone (arrow indicates a cell expressing only HA-hRAMP3), and the right panel shows the two channels merged with DAPI nuclear stain in blue (arrow indicates a cell expressing both FLAG-hGPR30 and HA-hRAMP3). The regions indicated by the white boxes are enlarged in the corresponding panels below and arrows indicate co-localization at the plasma membrane. The experiment was repeated three times with similar results.
We next sought to determine whether the interaction of GPR30 and RAMP3 has functional consequences in vivo. First, we determined the gene expression levels of Gpr30 and Ramp3 in the hearts of wild-type mice. Expression of both Ramp3 (Fig. 3A) and Gpr30 (Fig. 3B) was detected in the hearts of male mice, female mice in diestrus and estrus, and female mice that have been ovariectomized to deplete endogenous E2. For both genes, we observed modest increases in females in estrus compared with intact females in diestrus. Ovariectomized females had a statistically significant reduction in both Gpr30 and Ramp3 expression compared with diestrus. Ovariectomized females had a statistically significant reduction in both Gpr30 and Ramp3 expression compared with intact females in diestrus. Though the differences in expression between males and females in the phases of the estrus cycle are modest, these findings, particularly the reduced gene expression in the ovariectomized females, indicate that cardiac Gpr30 and Ramp3 gene expression levels correlate with endogenous E2.

Using heart tissue from Ramp3+/+ and Ramp3−/− mice, we investigated GPR30 protein levels and localization by performing subcellular fractionation and western blots for GPR30. In pooled heart lysates (n = 3) from Ramp3+/+ mice, we detected robust expression of GPR30 protein at the expected molecular size (50 kD) in the membrane fraction and very little in the cytosolic fraction (Fig. 4A). By contrast, pooled Ramp3−/− heart lysates (n = 3) showed reduced membrane GPR30 levels (GPR30-integrated density at membrane relative to actin, Ramp3−/− = 0.27 compared to Ramp3+/+ = 1.0). The Ramp3−/− hearts also show a concomitant increase in cytosolic GPR30 protein relative to wild-type (Fig. 4A). To determine whether cardiac expression and localization of GPR30 protein differ by sex, we performed the same experiment using male and female hearts side-by-side. Figure 4B shows the membrane fraction from these samples. These data show that Ramp3+/+ hearts have more membrane-localized GPR30 than Ramp3−/− hearts in both sexes. Furthermore, female hearts have more overall GPR30 at the membrane compared with males, a difference that was statistically significant for wild-type animals (relative GPR30-integrated density at membrane: females, Ramp3+/+ = 1.0 and Ramp3−/− = 0.43; males, Ramp3+/+ = 0.41 and Ramp3−/− = 0.10).

To explore the effect of RAMP3 on GPR30 localization in the setting of cardiovascular disease, we utilized RenTgMK mice. The RenTgMK mouse is a well-described model of angiotensin II-mediated chronic hypertension and cardiac hypertrophy (Caron et al. 2002, 2004, 2005). We have previously shown that Ramp3 gene expression is increased in the hearts of RenTgMK mice of both sexes compared with wild-type, and this heart disease-related upregulation of Ramp3 is greatest in females (Barrick et al. 2012). For the current study, we generated RenTgMK mice lacking Ramp3 (RenTgMK;Ramp3−/−) and RenTgMK mice with intact RAMP3 (RenTgMK;Ramp3+/+), isolated heart tissue, and performed subcellular fractionation and western blotting to determine GPR30 localization in this model of heart disease. Consistent with our findings in wild-type animals, we detected more GPR30 protein at the membrane in RenTgMK females than in males (relative GPR30-integrated density at membrane: females = 1.0, males = 0.58; Fig. 4C). Using replicate samples, we also observed that RenTgMK;Ramp3−/− mice had reduced GPR30 at the plasma membrane compared with RenTgMK;Ramp3+/+ mice (relative GPR30-integrated density at membrane: females = 1.0, males = 0.58; Fig. 4C).
Localization of GPR30 and RAMP3 in vivo. (A, B, C and D) GPR30 immunoblots of fractionated cardiac lysates. Membrane-enriched and cytosolic fractions were prepared by ultracentrifugation, and western blotting for GPR30 protein was performed. The integrated density of GPR30 normalized to actin for each lane is listed below each blot, with the first lane set equal to 1.0. (A) GPR30 western blot of cardiac lysates of Ramp3+/+ and Ramp3−/− mice (n=3 animals per genotype). GPR30 is reduced in the membrane fraction and increased in the cytosolic fraction in Ramp3−/− vs Ramp3+/+ hearts. (B) GPR30 western blot of the plasma membrane fraction of cardiac lysates from male and female Ramp3+/+ and Ramp3−/− mice (n=3 animals per group). Females have more membrane-localized GPR30 than males, and loss of Ramp3 reduces membrane GPR30 levels in both sexes. (C) Western blot of the plasma membrane (P) and cytosolic (C) fractions of pooled RenTgMK male and female hearts. (D) Western blot of the plasma membrane (P) and cytosolic (C) fractions of cardiac lysates from male and female RenTgMK; Ramp3+/+ and RenTgMK; Ramp3−/− mice. Loss of Ramp3 localized GPR30 than males, and loss of Ramp3 reduces membrane GPR30 compared with males across all conditions, and this sex difference is statistically significant in Ramp3+/+ and RenTgMK; Ramp3+/+ hearts. Thus, female mice have significantly increased membrane-localized GPR30 protein compared with males, and there is a trend of protein mislocalization in male and female Ramp3−/− and RenTgMK; Ramp3−/− hearts.

Finally, we investigated whether pharmacological activation of GPR30 is cardioprotective in the RenTgMK model of heart disease and whether these effects are dependent on RAMP3. We treated male and female RenTgMK;Ramp3+/+ and RenTgMK;Ramp3−/− mice with G-1, the specific agonist for GPR30, or a placebo for a period of 40 days and then performed cardiovascular phenotyping. First, we measured blood pressure to determine whether G-1 treatment affected the hypertensive phenotype of the RenTgMK mice. We found no significant change in blood pressure with G-1 treatment in male mice (RenTgMK;Ramp3+/+ placebo = 145.6 ± 22.4 mmHg, RenTgMK;Ramp3+/+ G-1 = 148.7 ± 25.9 mmHg) and RenTgMK;Ramp3−/− placebo = 150.3 ± 38.6 mmHg, RenTgMK;Ramp3−/− G-1 = 159.5 ± 25.1 mmHg) or female mice (RenTgMK;Ramp3+/+ placebo = 128.5 ± 25.6 mmHg, RenTgMK;Ramp3+/+ G-1 = 118.0 ± 25.0 mmHg and RenTgMK;Ramp3−/− placebo = 135.8 ± 27.4 mmHg, RenTgMK;Ramp3−/− G-1 = 140.1 ± 38.8 mmHg).
Next, we examined cardiac fibrosis. Consistent with other studies (Jessup et al. 2010), we found that there were no overt differences in interstitial fibrosis between the genotypes or with G-1 treatment in male mice (Fig. 5A and B). However, G-1 treatment did result in a statistically significant reduction in perivascular fibrosis (Fig. 5C and D) in the hearts of RenTgMK;Ramp3+/+, but not RenTgMK;Ramp3−/−, male mice. We also examined female hearts and found no significant differences in either perivascular or interstitial fibrosis.

We also found interesting changes in the LV:BW ratio of these mice. The LV:BW ratio of RenTgMK;Ramp3+/+ male mice was significantly reduced with G-1 treatment compared with placebo (Fig. 6A). RenTgMK;Ramp3−/− males, on the other hand, had no reduction in their LV:BW ratio with G-1 treatment. Female mice of both genotypes had no significant response to G-1 treatment. BWs did not differ by genotype or treatment condition for males (RenTgMK;Ramp3+/+ placebo=24.36±4.19 g, RenTgMK;Ramp3+/+ G-1=23.79±2.98 g and RenTgMK; Ramp3−/− placebo=23.19±2.73 g, RenTgMK;Ramp3−/− G-1=23.96±3.39 g) or females (RenTgMK;Ramp3+/+ placebo=18.44±1.60 g, RenTgMK;Ramp3+/+ G-1=19.23±2.21 g and RenTgMK;Ramp3−/− placebo=20.05±1.77 g, RenTgMK;Ramp3−/− G-1=20.15±1.75 g). In addition to determining LV:BW ratios, we measured cardiomyocyte cross-sectional area, which revealed results consistent with the heart weight findings. Only male RenTgMK mice with intact Ramp3 showed a significant reduction in cardiomyocyte area with G-1 treatment, while females or males lacking Ramp3 did not respond to G-1 treatment (Fig. 6B and C).

**Discussion**

The identification of novel GPCR–RAMP interactions is of great interest because this complex forms a pharmacologically tractable interface, which could potentially be manipulated for the treatment of human disease (Sexton et al. 2009). In the current study, we identified GPR30, an E2 receptor with important functions in the cardiovascular system (Olde & Leeb-Lundberg 2009, Nilsson et al. 2011, Prossnitz & Barton 2011), as a novel target for RAMP3, a modifying protein also known for its sex-dependent cardioprotective effects (Barrick et al. 2012). The association of GPR30 with a RAMP is of particular interest because this has the potential to clarify much of the controversy that still surrounds GPR30’s cellular localization, ligand-binding specificity, and function. Furthermore, GPR30 is the first family A GPCR to be shown to interact with an RAMP.

In this study, we have made use of both standard and newly available techniques in the field to provide compelling evidence for the GPR30–RAMP3 interaction. BRET, already well described for its utility in testing protein–protein interactions in general, has recently been used as an elegant and quantitative method to interrogate GPCR–RAMP interactions (Heroux et al. 2007, Harikumar et al. 2009). Here, we use this method to reveal a robust interaction between GPR30 and RAMP3 that is equivalent to that observed with CLR, the canonical RAMP-associated receptor. Co-immunoprecipitation of the epitope-tagged GPR30 and RAMP3 proteins further supports this conclusion. In the past, the use of confocal microscopy to test the ability of GPCRs to enhance the localization of RAMPs in the plasma membrane was the standard method by which the association of receptors with RAMPs had been tested (Harikumar et al. 2009). Similarly, with this technique, we found that GPR30 and RAMP3 co-localize, and expression of GPR30 enhances RAMP3 localization to the cell surface. This provides further evidence for an interaction between the two proteins and shows that the association of GPR30 and RAMP3 alters the localization of this complex.

In addition to the localization effects observed in vitro, RAMP3 may also affect localization of GPR30 in vivo, as absence of RAMP3 results in a trend of mislocalized GPR30 in both normal mouse heart tissue and in heart tissue on a background of cardiovascular disease. Sex differences in GPR30 localization were also observed, as the hearts of female mice have a significantly increased proportion of GPR30 protein at the plasma membrane compared with males when Ramp3, an estrogen regulated gene, is present. Most importantly, these in vivo differences have functional consequences, as pharmacological activation of GPR30 reduces cardiac hypertrophy and perivascular fibrosis in male mice with intact Ramp3, while genetic loss of Ramp3 eliminates this cardioprotective effect. These effects were independent of blood pressure, which is consistent with previous studies showing that chronic G-1 treatment does not affect blood pressure under hypertensive conditions in intact male or female rats (Lindsey et al. 2009, 2011, Jessup et al. 2010, Wang et al. 2012). Thus, it is likely that this cardioprotection is due to direct effects of GPR30–RAMP3 function in the heart, which is influenced by the localization of the protein complex.

Interestingly, we found that the reduction of cardiac hypertrophy and perivascular fibrosis is only observed in male mice, indicating that the protective effect of GPR30
Figure 5
The effect of in vivo activation of GPR30 on cardiac fibrosis. (A) Masson’s trichrome staining of interstitial fibrosis in the left ventricle of male RenTgMK;Ramp3+/+ and RenTgMK;Ramp3−/− mice treated with 6 mg continuous release pellets of G-1 or placebo for 40 days, (B) with quantitation. No overt differences in interstitial fibrosis were observed between the genotypes or with G-1 treatment. (C) Masson’s trichrome staining of perivascular fibrosis in the left ventricle of male RenTgMK;Ramp3+/+ and RenTgMK;Ramp3−/− mice treated with G-1 or placebo, (D) with quantitation. G-1 treatment resulted in a statistically significant reduction in perivascular fibrosis in RenTgMK;Ramp3+/+ males but not in RenTgMK;Ramp3−/− males or female mice of either genotype. n = 5–9 animals per group.
**Figure 6**
The effect of *in vivo* activation of GPR30 on left ventricular hypertrophy. (A) Left ventricle to body weight (LV:BW) ratios of male and female RenTgMK;Ramp3+/+ and RenTgMK;Ramp3−/− mice treated with the G-1 or placebo. Male RenTgMK;Ramp3+/+ mice show a statistically significant reduction in LV:BW ratio with G-1 treatment (*P* < 0.05). (B) Hematoxylin and eosin staining of the left ventricles of male and female RenTgMK;Ramp3+/+ and RenTgMK;Ramp3−/− mice. (C) Cardiomyocyte cross-sectional area measurements of male and female RenTgMK;Ramp3+/+ and RenTgMK;Ramp3−/− mice. Male RenTgMK;Ramp3+/+ mice show a statistically significant reduction in cardiomyocyte area with G-1 treatment (*P* < 0.001). *n* = 5–9 animals per group.
in the heart is both RAMP3 and sex dependent. Our previously published work has demonstrated that RenTgMK;Ramp3−/− males at 5–6 months of age have exacerbated cardiac hypertrophy. We intentionally performed our cardiovascular phenotyping experiments in mice beginning at 2 months of age, and as expected at this early time point, the LV:BW ratios and cardiomyocyte areas did not differ in mice lacking Ramp3. Thus, Ramp3 genotype-dependent effects do not confound the interpretation of our results from the G-1 treatment experiments. Figure 7 models our proposed explanation for why the effectiveness of G-1 treatment was dependent on sex and Ramp3 genotype. We hypothesize that because female mice have increased GPR30 at the cell membrane compared with males and high levels of the estradiol (E2), they remain cardioprotected even when Ramp3 is absent. Males have reduced membrane GPR30 and low E2 levels and thus lack the natural cardioprotection seen in females. G-1 treatment can improve the cardiovascular phenotype only if the male expresses Ramp3, which may maintain GPR30 localization at the cell membrane, allowing for efficient response to ligand treatment.

Figure 7
A model of GPR30- and RAMP3-mediated cardioprotection. Female mice have increased GPR30 at the cell membrane compared with males and high levels of the estradiol (E2). Therefore, regardless of G-1 treatment, females may remain cardioprotected even when Ramp3 is absent. Males have reduced membrane GPR30 and low E2 levels and thus lack the natural cardioprotection seen in females. G-1 treatment can improve the cardiovascular phenotype only if the male expresses Ramp3, which may maintain GPR30 localization at the cell membrane, allowing for efficient response to ligand treatment.

RAMP-mediated effects in addition to localization, such as downstream signaling. Future studies will be directed at determining whether and how RAMP3 alters GPR30-mediated cell signaling.

Our results are consistent with our previous studies showing a sex-dependent cardioprotective role for RAMP3 (Barrick et al. 2012), and our findings also complement studies by others including Jessup et al. (2010) showing that G-1 treatment significantly reduces cardiomyocyte hypertrophy in intact female rats with salt-sensitive hypertension. Although G-1 treatment reduces interstitial fibrosis in ovariectomized female rats (Kang et al. 2012, Wang et al. 2012), the reduction in perivascular fibrosis with G-1 treatment in male mice shown here is unique. To our knowledge, this is the first report of GPR30 agonist-induced cardioprotection in a genetic mouse model of cardiovascular disease, with the additional discovery of sex differences. The requirement for RAMP3 to mediate these effects is entirely novel.

Our results demonstrate for the first time that GPR30 and RAMP3 interact. This interaction has functional consequences on the localization of these proteins, and we show that RAMP3 plays a critical and sex-dependent role in GPR30-mediated cardioprotection. GPR30–RAMP3 is a novel pathway that may contribute to sex differences in cardiovascular disease susceptibility and progression, and ultimately, this pathway could potentially be targeted for sex-tailored treatment for cardiovascular disease.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by funds from the National Institutes of Health (NIH/NHLBI HL091973 and NIH/NICHD HD068860 and HD035041 to K M C and F30HL104778 to P M L), an American Heart Association Established Investigator Award (to K M C), the Swedish Research Council (VR2009-4077 to L M F and F30HL104778 to P M L), the Swedish Cancer Society (CAN2011/628 to L M F L-L) and the Swedish Research School for Drug Science FLÄKT to S B.

Author contribution statement
P M L, S B, and C D B designed and performed experiments and analyzed the results. P M L wrote the manuscript with input from all coauthors. L M F L-L and K M C designed experiments, analyzed data, and provided the conceptual framework for the research.

Acknowledgements
The authors thank James Barwell, Dan Rathbone, and David Poyner for their helpful discussions and insights. They also thank Manyu Li for assistance with cloning, and Kim Fritz-Six and Mahita Kadmiel for assistance with experiments.
References


Cascio W, Rockman H & Smithies O 2004 Cardiac hypertrophy and transition to heart failure in a sex-dependent manner. Journal of Molecular Endocrinology 36 81–89. (doi:10.1530/jme.1.01825)

Received in final form 8 May 2013
Accepted 14 May 2013
Accepted Preprint published online 14 May 2013